225-Actinium production at TRIUMF: combining physics, engineering, and chemistry for medicine
Event Start:
2020-07-16T16:00:00
Event End:
2020-07-16T17:00:00
Event Information:
225Ac is an alpha-emitting radionuclide that has shown remarkable potential for use in targeted alpha therapy of late stage metastatic diseases, most notably prostate cancer. However, 225Ac-radiopharmaceutical development remains limited by the insufficient availability of the radionuclide, despite multiple efforts to increase 225Ac supply via alternative methods that avoid the use of nuclear weapons material.
Event Location:
Connect via zoom
Speaker:
Andrew Robertson (UBC)
Related Upcoming Events:
Add to Calendar
Event Start:
2020-07-16T16:00:00
Event End:
2020-07-16T17:00:00
225-Actinium production at TRIUMF: combining physics, engineering, and chemistry for medicine
Event Information:
225Ac is an alpha-emitting radionuclide that has shown remarkable potential for use in targeted alpha therapy of late stage metastatic diseases, most notably prostate cancer. However, 225Ac-radiopharmaceutical development remains limited by the insufficient availability of the radionuclide, despite multiple efforts to increase 225Ac supply via alternative methods that avoid the use of nuclear weapons material.
Event Location:
Connect via zoom